Search the Newsreel

AbbVie’s Growth Now Leans On A Single Molecule

AbbVie's future growth is heavily reliant on a single drug, SKYRIZI, which is projected to account for close to one-third of the company's total revenue in 2026. While the patent for SKYRIZI extends well into the 2030s, the company faces a challenge with its …

Viemed Healthcare Q2 Revenue Rises 24 Percent to Record $78.1 Million

Viemed Healthcare Announces Second Quarter 2026 Financial Results

AbbVie Inc. stock underperforms Monday when compared to competitors

AbbVie Inc. (ABBV) stock fell 2.33% on Monday, closing at $245.10, despite a generally positive trading session where the S&P 500 and Dow Jones Industrial Average both saw gains. This marks the third consecutive day of losses for AbbVie, underperforming its competitors. The article …

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

AbbVie (ABBV) reported another "strong" quarter operationally, with investor attention increasingly PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in

AbbVie Inc. 2026: Revenue $16.99B, EPS $2.03— 10-Q Summary

AbbVie Inc. reported its 2026 quarterly results, with revenue reaching $16.99 billion and diluted EPS at $2.03, marking significant growth over the prior year. This performance was attributed to strong sales of key brands like Skyrizi, Rinvoq, and neuroscience products, despite a decline in …

Riverview Bancorp (NASDAQ:RVSB) Director Jon Louis Girod Acquires 2,000 Shares of Stock

Riverview Bancorp Director Jon Louis Girod recently acquired 2,000 shares of RVSB stock for $10,480, increasing his ownership to 2,000 shares. The company reported quarterly EPS of $0.08 and revenue of $15.01 million, surpassing analyst expectations, and pays a quarterly dividend of $0.02 per …

Esophageal Cancer Market to Accelerate at a CAGR of 6% During the Forecast Period (2026–2036), Driven by the Advancements in Targeted and Immunotherapy Treatments | DelveInsight

DelveInsight Business Research LLP The esophageal cancer market landscape is poised for substantial transformation with the introduction of innovative therapeutic approaches, including antibody-drug conjugates (ADCs), next-generation targeted therapies, and combination immunotherapy regimens. Emerging candidates such as Telisotuzumab adizutecan (AbbVie) highlight this progress by delivering …

Viemed Healthcare Q2 Earnings Preview

* Viemed Healthcare (VMD [https://seekingalpha.com/symbol/VMD]) is scheduled to announce Q2 earnings results on Tuesday, August 4th, before market open. * The consensus EPS Estimate is $0.12 [https://seekingalpha.com/symbol/VMD/earnings/estimates] and the consensus Revenue Estimate is $78M * Over the last 1 year, VMD has beaten EPS …

Canaccord raises Abbvie stock price target to $290 on Q2 beat

Canaccord Genuity increased its price target for Abbvie Inc. (NYSE:ABBV) to $290 from $282, maintaining a Buy rating, following the company's strong second-quarter performance. Abbvie exceeded revenue and earnings expectations, particularly in its Immunology and Neuroscience franchises, leading to a raised 2026 revenue guidance. …

AbbVie Earnings: Maintaining Our Fair Value Estimate Following a Steady Second Quarter

Morningstar is maintaining its $200 fair value estimate for wide-moat AbbVie following a strong second quarter, which saw 10.2% top-line growth and 22.9% adjusted diluted EPS growth. The company's immunology portfolio, particularly Skyrizi and Rinvoq, continues to drive strong double-digit growth, despite increasing competition. …

ABBV Q2 Earnings Call Balances Growth With Apogee Dilution

AbbVie Inc. ABBV paired strong product momentum with a more complex 2026 outlook. Management raised revenue expectations, while the planned Apogee Therapeutics acquisition pushed adjusted earnings guidance modestly lower. The call focused on Skyrizi, Rinvoq and neuroscience growth, the case for Apogee and a …

(VMD) Movement as an Input in Quant Signal Sets

This article analyzes Viemed Healthcare Inc. (NYSE: VMD) using AI-generated quant signals. It identifies a neutral near and mid-term outlook with a long-term positive bias, noting a mid-channel oscillation pattern. The analysis presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry, target, …

AbbVie (NYSE: ABBV) lifts 2026 revenue to 31,992 million

UFO Moviez Consolidated June 2026 Net Sales at Rs 110.69 crore, up 3.81% Y-o-Y

Dimensional Fund Advisors LP Has $52.22 Million Stock Position in Navient Corporation $NAVI

Navient Set to Report Q2 Earnings: What's in Store for the Stock?

Navient Corporation NAVI is scheduled to report second-quarter 2026 results on Aug. 06, before the opening bell. Its quarterly revenues and earnings are expected to have declined year over year. In the last quarter, NAVI's results benefited from lower expenses and a decline in …

Saudi’s View United Real Estate rolls out 4 new tranches of $2.6mln sukuk

BrightView (BV) Reports Earnings Tomorrow: What To Expect

AbbVie Quietly Solved Its Biggest Problem—Now What?

AbbVie (ABBV) has successfully diversified its business beyond its previous dependence on Humira, with strong Q2 revenue and earnings growth driven by its Immunology and Neurosciences segments. Analysts maintain a "Moderate Buy" rating, anticipating the stock could reach $300 within 12 months, despite a …

Viewtrix Technology Sets Out Board and Committee Structure

Viewtrix Technology Refreshes Board with New Independent Director Nominee

Dimensional Fund Advisors LP Buys 192,376 Shares of BrightView Holdings, Inc. $BV

Dimensional Fund Advisors LP increased its stake in BrightView Holdings, Inc. by 3.8% in the first quarter, acquiring an additional 192,376 shares, bringing its total holdings to 5.27 million shares. This represents about 5.59% of the company, which is 92.41% institutionally owned. BrightView recently …

AbbVie (ABBV) Stock Faces A Pivotal Growth Handoff After Guidance Lift

AbbVie Number of Employees 2026 | Employee Count & Headcount Data

As of March 2026, AbbVie (ABBV) has approximately 57,960 total employees worldwide, a growth of 11.0% since 2023. The company is actively hiring, with 2,862 job postings in 2026, and its workforce is concentrated in the United States, followed by India and Ireland. The …

LatentView Analytics reports 6 pc decline in Q1 profit

SUPV Stock Price and Chart — NYSE:SUPV

This article provides an overview of Grupo Supervielle S.A. (NYSE: SUPV) stock performance, key financial statistics, and company details. It includes price changes over various periods, market capitalization, dividend yield, EPS, revenue, and information about the company's operational segments and headquarters. The article also …

Avient (AVNT) Nears Its Earnings Test, Is The 14% Undervalued View Priced In?

View United Real Estate Development Company Revenue Breakdown – TADAWUL:9591

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie has revised its full-year profit forecast downwards as a direct consequence of its recent acquisition of Apogee Therapeutics. This adjustment reflects the financial impact and integration costs associated with the acquisition, signaling a change in the company's expected earnings for the fiscal year.

Riverview Bancorp (NASDAQ:RVSB) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded Riverview Bancorp (NASDAQ:RVSB) from "hold" to "sell," leading to an average "Reduce" rating for the company from MarketBeat. Despite beating earnings and revenue expectations in its recent quarterly report, Riverview Bancorp posted a negative net margin. The stock opened at …

RVSB|Riverview Bancorp Inc|Price:5.300|Chg%:+0.010

Riverview Bancorp Inc (RVSB) shows healthy fundamentals and good growth potential, with a "Buy" rating from analysts and a highest price target of $7.00. The stock is considered fairly valued and institutional ownership is very high, despite a recent decrease in holdings. The company …

AbbVie (ABBV) Stock Could Sit Below Fair Value While Earnings Look Rich

Riverview Bancorp Inc Revenue Breakdown – NASDAQ:RVSB

Riverview Bancorp Inc. (NASDAQ: RVSB) reported its revenue breakdown, with Banking Operations, Trust and Investment Services being its top-performing segment, generating $43.08 million last year, down from $50.60 million the previous year. All of the company's revenue came from the United States, totaling $43.08 …

Why AbbVie Stock Slumped Today

AbbVie's stock fell by nearly 3% after its second-quarter earnings report, despite strong revenue growth, because its adjusted profitability of $3.65 per share missed analyst estimates of $3.71. Additionally, the company slightly cut its 2026 profitability outlook due to its acquisition of Apogee Therapeutics, …

AbbVie's Skyrizi and Rinvoq Launches Support Lengthy Patent Protection and a Wide Moat

AbbVie's key drugs Skyrizi and Rinvoq are providing strong support for the company's lengthy patent protection and wide economic moat. Despite biosimilar competition impacting Humira revenue in 2023, AbbVie returned to growth in 2024, demonstrating the resilience of its diversified portfolio. The company maintains …